The drug "Gliatilin" is included in the group of central cholinomimetics with a primary effect on the central nervous system. The drug contains 40.5% of choline, metabolically protected, which ensures its release in the brain.
The medication is available in the form of capsules for oral administration and ampoules for administration of intramuscular and intravenous.
The active substance is choline alfoscerate. The capsule contains 400 mg of the active ingredient, in the ampoule - 1000 mg.
The active substance, getting into the body, is split into glycerophosphate and choline under the influence of enzymes. Choline is involved in the biosynthesis of one of the main mediators in nervous excitation (acetylcholine). Glycerophosphate is the precursor of frsfatidylcholine (a phospholipid in the neural membrane).
Accumulation occurs mainly in the brain (up to 45% of the level in the blood), liver and lungs. In the form of carbon dioxide, 85% is excreted by the lungs. 15% goes through the intestines and kidneys.
The drug does not affect the reproductive cycle, does not have mutagenic and teratogenic properties.
The medicine “Gliatilin” is able to improve the transmission of nerve impulses in cholinergic neurons, cerebral blood flow, positively affect the functions of receptors and the plasticity of neuronal membranes, activate structures in the reticular formation, enhance metabolic processes, and restore consciousness in brain injuries of a traumatic nature.
The active component of the drug has a corrective and preventive effect on certain pathogenic factors in the involutive psycho-organic syndrome - a change in the membranes of neurons of the phospholipid composition and a decrease in cholinergic activity.
The drug "Gliatilin" is indicated in the acute period of traumatic brain injury with a predominantly stem-type lesion (coma, impaired consciousness, signs of lesions in the brain stem, and others). The medicine is prescribed for hemorrhagic and ischemic stroke in the recovery and acute phases. The drug "Gliatilin" instruction recommends and with involutional or degenerative brain syndromes of a psycho-organic nature, the consequences of cerebrovascular insufficiency. These conditions include multi-infarct dementia, Alzheimer's disease, as well as conditions accompanied by confusion, decreased motivation, ability to concentrate, initiative, and the development of disorientation. The drug "Gliatilin" instruction recommends for emotional instability, changes in the behavioral sphere, irritability, senile pseudomelancholy, decreased interest.
The drug is not prescribed for lactation, hypersensitivity, pregnancy.
The medicine "Gliatilin". Instructions for use
The drug is prescribed intramuscularly or slowly intravenously with the development of acute conditions - 1000 mg per day. Inside, with cerebrovascular insufficiency of a chronic course and syndromes of dementia, the drug "Gliatilin" instruction recommends taking 400 mg three times a day.
The duration of the course is from three months to six months.
A side effect when using the drug is nausea. In case of an overdose, this symptom may intensify. If you experience nausea, you should reduce the dosage of the medication and consult a doctor.
The medicine "Gliatilin" is prescribed to children quite often. As the practice of using the drug in patients aged one year and older shows, the medication is well tolerated. Means "Gliatilin" for children is a tool that helps normalize development. The drug has a positive effect on concentration. Some parents note significant progress in the development of children. A medication is very effective with long-term use (two to three months, at least).